1National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
2MRI Research, GE Healthcare (China), Beijing, China
3GE Healthcare (China), Beijing, China
4Department of Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, shenzhen, China
5Department of Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Presenting Author: Zheng Zeng
Synopsis
Motivation:
Goals:
Approach:
Results:
Preview figure
Full abstract & presentation
The full text, figures, and any recorded presentation for this abstract are not shown here. Log in if you are a member or registered attendee with access.
Full abstracts, figures, and presentations for 2026 ISMRM-ISMRT Annual Meeting and Exhibition are available to registered attendees. This content becomes freely available to the public on 13 May 2028.
To request or purchase access, contact the ISMRM Central Office at support@ismrm.org.
1. Liu SL, Sun XS, Yan JJ, et al. Optimal cumulative cisplatin dose in nasopharyngeal carcinoma patients based on induction chemotherapy response. Radiother Oncol. 2019;137:83-94. doi:10.1016/j.radonc.2019.04.020 [doi]
2. Wang HJ, Cai Q, Huang YP, et al. Amide Proton Transfer-weighted MRI in Predicting Histologic Grade of Bladder Cancer. Radiology. 2022;305(1):127-134. doi:10.1148/radiol.211804 [doi]
3. Choi SH. Can Amide Proton Transfer MRI Distinguish Benign and Malignant Head and Neck Tumors?. Radiology. 2018;288(3):791-792. doi:10.1148/radiol.2018180914 [doi]